ClinicalTrials.gg
Not yet recruitingNCT06042426Updated Sep 18, 2023

Effects of Perioperative Intravenous Dexamethasone in Clinical Outcomes After Total Knee Arthroplasty in a Hispanic Population

A Phase 4 interventional study of Dexamethasone and Morphine in Osteoarthritis, Knee, sponsored by University of Puerto Rico. Not yet recruiting at 1 site in Puerto Rico. Open to participants aged 24 Years and older. Per ClinicalTrials.gov, last updated 2023-09-18.

Sponsored by University of Puerto Rico · Phase 4, Interventional, and Treatment

How we know

From the registry’s dates

  • Primary completion was expected by Feb 2024, 2 years 9 months ago, but the record still lists the study as not yet recruiting.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 4
Study type
Interventional
Enrollment
100
Allocation
Randomized
Ages
24 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 12 studies testing dexamethasone in Osteoarthritis, Knee — 2 open to participants now, 2 under way, none of them phase 3. Dexamethasone · Osteoarthritis, Knee.

Planned enrollment
4th of 12
100 · median 90
Started
2023
the only one that year
Phase 4
9 of 12
1 open now
Registered
7th of 12
by date
Lead sponsor
1 of 12
University of Puerto Rico

Among the 12 studies testing dexamethasone in Osteoarthritis, Knee, this one is the 4th largest by planned enrollment, is the only one that started in 2023, is one of 9 in phase 4, and was the 7th registered.

Osteoarthritis, Knee

3,297 studies on the registry are indexed under Osteoarthritis, Knee; 623 are open to participants now.

Browse Osteoarthritis, Knee studies →

Open to participants now

2 of the 12 studies testing dexamethasone in Osteoarthritis, Knee are open now, in 2 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 2 open studies →

About dexamethasone

Dexamethasone: first FDA approval 1958 (DECADRON), first EMA approval 2010. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 384 Osteoarthritis, Knee studies recruiting now, 178 (46%) set no upper age limit and 113 (29%) stop at 75 or younger; 19 take children under 18; 39 take healthy volunteers.

This study: 24 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 12 studies testing dexamethasone in Osteoarthritis, Knee, or all of them as a file.
02

Study summary

The purpose of this study is to evaluate the efficacy of an intravenous (IV) perioperative dexamethasone regime in the clinical outcomes after a robotic-assisted Total Knee Arthroplasty (TKA) in a Hispanic population. The study aims to propose an alternative to opioid-based pain treatment following TKA. The study hopefully validates the use of a two-dose, 8mg intravenous dexamethasone regimen for improving pain and range of motion scores in patients undergoing primary, unilateral TKA for osteoarthritis. One dose will be applied prior to incision and the other at post-operative day (POD) 1.

03

Conditions studied

  • Osteoarthritis, Knee

Keywords

  • TKA
  • Primary osteoarthritis
04

Who can participate

Ages eligible
24 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Patient with Hispanic self-identification
  • Primary robotic-assisted TKA for treatment of primary osteoarthritis
  • Age ≥ 21
  • Receiving seven days of inpatient rehabilitation after medical discharge
  • Patient with adequate glycemic control (\<7.5%)
  • Patients who provide written

Exclusion criteria

Exclusion Criteria:

  • Age ≤ 21
  • Chronic use prior to surgery
  • Previous allergies or adverse reactions to steroid drugs
  • Indications for surgery other than primary osteoarthritis
  • History of narcotics abuse such as opioids
  • Surgeries performed without robotic-assistance
  • Outpatient or Home rehabilitation programs after medical discharge
  • Requirement of revision surgery orthopaedic implants
  • Patients with inadequate glycemic control (≥7.5%)
  • Other medical conditions, such as osteoporosis, fungal infections, glaucoma, joint infections, peptic ulcer disease which could worsen with steroid administration.
Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

HbA1c

A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

05

Study design

Phase
Phase 4
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Single (Investigator)
Enrollment
100 participants (estimated)

Study arms

  • Experimental
    Patients receiving intravenous dexamethasone

    Drug: Dexamethasone

  • Active comparator
    Patients receiving intravenous morphine and oral oxycodone

    Drug: Morphine · Drug: Oxycodone and acetaminophen

Interventions

06

What researchers measure

Primary outcomes

  1. POD 1 Visual Analogue Scale Pain Scores

    Range: 0-10 (10 indicates highest degree of pain)

    Time frame: Measured at 7:00AM day after surgery

  2. POD 2 Visual Analogue Scale Pain Scores

    Range: 0-10 (10 indicates highest degree of pain)

    Time frame: Measured at 7:00AM two days after surgery

  3. POD 3 Visual Analogue Scale Pain Scores

    Range: 0-10 (10 indicates highest degree of pain)

    Time frame: Measured at 7:00AM three days after surgery

  4. POD 1 Range of Motion

    Time frame: Measured at 7:00AM the day after surgery

  5. POD 2 Range of Motion

    Time frame: Measured at 7:00AM two days after surgery

  6. POD 3 Range of Motion

    Time frame: Measured at 7:00AM three days after surgery

Secondary outcomes

  1. Daily Dextrose Concentration (mg/dL)

    Time frame: Measured at 7:00AM for 3 days after surgery

  2. Length of Stay

    Measured in days

    Time frame: From hospital admission to the date of discharge (About 3 days)

07

Study locations

1 site
  • University of Puerto Ric-Dr. Federico Trilla Hospital
    Carolina, 00984, Puerto Rico
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Start is estimated for Sep 2023; primary completion for Feb 2024, 5 months later.

Of 88 non-industry phase 4 interventional studies under Osteoarthritis, Knee, half reached primary completion within 19 months of starting (the median), counting those still running; a quarter within 10 and three quarters within 32. This study's planned 5 months is below that.

Counting every sponsor, half of 97 studies reached it within 19 months; a quarter within 10 and three quarters within 36.

How these figures are worked out, and which studies are left out of them.

Registered
Aug 3, 2023
First posted
Sep 18, 2023
StartEst.
Sep 2023
Primary completionEst.
Feb 2024
CompletionEst.
Feb 2024
Last update
Sep 18, 2023
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Sep 18, 2023, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT06042426
Lead sponsor
University of Puerto Rico
Responsible party
Sponsor
First posted
Sep 18, 2023
Start date
Sep 2023 (estimated)
Primary completion
Feb 2024 (estimated)
Completion
Feb 2024 (estimated)
Last update
Sep 18, 2023

Study contacts

Alexandra M Claudio Marcano, MD
Contact
alexandra.claudio1@upr.edu
787-221-5210
Norberto J Torres, MD
Contact
norberto.torres1@upr.edu
787-403-8109
Antonio M López Otero, MD
principal investigator · Orthopaedic Surgery Section, University of Puerto Rico Medical Sciences Campus San Juan, Puerto Rico

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Aug 2023. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Dexamethasone

Start the discussion